The multi-dimensional impact of captopril modification on human serum albumin

Captopril is a thiol drug, widely used for the management of hypertension and cardiovascular diseases. Reactive thiols are found to covalently modify the cysteines of plasma proteins and affect their structure and function. Human serum albumin (HSA) is prone to undergo modification by various low molecular weight compounds, including drugs. Cysteine34 (Cys34) in HSA has a free thiol group with antioxidant properties, considered to be the most redox-sensitive amino acid in plasma. Through mass-spectrometric analysis, we demonstrate for the first time that captopril forms a disulfide adduct at Cys34 residue and increases the protease susceptibility of HSA to trypsin. As evidenced by our biophysical and electron microscopy studies, HSA undergoes structural alteration, aggregation and morphological changes when treated with different captopril concentrations. Molecular dynamics studies further revealed the regions of secondary structural changes in HSA due to disulfide adduct formation by captopril at Cys34. It also elucidated the residues involved in the noncovalent interactions with captopril. It is envisaged that structural change in HSA may influence the efficacy of drug delivery as well as its own biological function. These findings may thus provide significant insights into the field of pharmacology intriguing further investigation into the effects of long-term captopril treatment.

Revealing the complexity of distinct manganese species-protein interactions through multi-spectroscopy

The effect of manganese (Mn) on protein conformation is closely related to its chemical species. To further realize the behavior of different species of Mn in vivo, this study is designed to analyze the separate and simultaneous interactions of Mn(ii) and Mn(iii) with bovine serum albumin (BSA) using multi-spectroscopy. The results demonstrated that the interaction of Mn(ii) or Mn(iii) with BSA is a process of static quenching and Mn(iii) formed a more stable complex. The binding constants and thermodynamic constants indicated that a 1:1 complex was formed between Mn(ii)/Mn(iii) and BSA through a moderate binding force, and hydrophobic interaction played an important role in the binding. UV-Vis spectroscopy, synchronous fluorescence spectroscopy and three-dimensional fluorescence spectroscopy results revealed that the conformation changes in BSA induced by Mn(ii)/Mn(iii) binding. The results of the ternary systems suggested that both Mn species interfered the interaction of the other with BSA. The conformation of BSA may change more to adapt to the simultaneous binding to Mn (ii) and Mn (iii) when two Mn species coexist.

Improvement of efficacy and decrement cytotoxicity of oxaliplatin anticancer drug using bovine serum albumin nanoparticles: synthesis, characterisation and release behaviour

To sustained release of an anticancer drug, oxaliplatin (OX), a non-toxic and biocompatible nanocarrier based on bovine serum albumin (BSA) were synthesised by desolvation method and characterised using Fourier-transform infrared (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM), atomic force microscopy (AFM) and dynamic light scattering. The results showed that the BSA nanoparticles (BSANPs) with a mean magnitude of 187.9 ± 1.2 nm have spherical morphology with a smooth surface and a uniform distribution. Furthermore, OX was loaded onto the BSANPs and the loading was confirmed by FTIR, AFM and FESEM techniques. The percentage of encapsulation efficiency and drug loading were determined by absorption spectroscopy (UV-vis). The drug release studies showed that release of OX from BSANPs exhibited slower release rate. However, the release kinetics followed the first-order kinetic for both of them with the non-Fickian release behaviour. The electrochemical analysis showed stability of OX loaded onto the BSANPs (OX@BSANPs) and confirmed the diffusion mechanism. Furthermore, the results of MTT assay revealed increasing of normal cell viability and cancer cell death in the OX@BSANPs compared to only OX. It was shown that the BSANPs could be safely used as a biocompatible nanocarrier for the sustained release of OX.